開示日時：2022/04/25 14:00:00
損益
| 決算期 | 売上高 | 営業益 | 経常益 | EPS |
| 2018.12 | 57,978,700 | 12,432,200 | 12,111,000 | 56.27 |
| 2019.12 | 68,618,400 | 21,059,700 | 20,747,300 | 95.81 |
| 2020.12 | 78,694,600 | 30,123,000 | 29,972,600 | 130.53 |
※金額の単位は［万円］
株価
| 前日終値 | 50日平均 | 200日平均 | 実績PER | 予想PER |
| 3,731.0 | 3,866.78 | 4,108.21 | 24.06 | 20.67 |
※金額の単位は［円］
キャッシュフロー
| 決算期 | フリーCF | 営業CF |
| 2018.12 | 4,140,300 | 11,907,400 |
| 2019.12 | 14,546,400 | 20,664,100 |
| 2020.12 | 14,362,400 | 20,503,500 |
※金額の単位は［万円］
▼テキスト箇所の抽出
April 25, 2022 Name of listed company: Chugai Pharmaceutical Co., Ltd. Code number: Head office: 4519 (Prime Market of Tokyo Stock Exchange) 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo President & CEO: Osamu Okuda Inquiries to: Toshiya Sasai Head of Corporate Communications Dept. Tel: +81-(0)3-3273-0554 F. Hoffmann-La Roche Announces First Quarter Sales 2022 F. Hoffmann-La Roche Ltd. (hereafter “Roche”) [Head Office: Basel, Switzerland. CEO: Severin Schwan] announced today its first quarter sales 2022 (January 1 – March 31, 2022). Roche owns 59.89% of Chugai’s outstanding shares (61.16% of voting rights) as of the end of December 2021. Its investor update and presentation materials can be found on its website (https://www.roche.com/). Chugai’s performance for the period of January 1 to March 31, 2022 is included in the announced Roche Group’s results. Investor Updates Reporting ###
